# Human Defensin 5 Inhibits Plasmodium yoelii Development in Anopheles stephensi by Promoting Innate Immune Response

## TL;DR

Human defensin 5 reduces malaria parasite development in mosquitoes by boosting their immune response.

## Contribution

HD5 inhibits Plasmodium yoelii in Anopheles stephensi via the Toll signaling pathway.

## Key findings

- HD5 treatment significantly reduced Plasmodium yoelii infection in mosquitoes.
- HD5 upregulated immune genes TEP1, MyD88, and Rel1 in mosquitoes.
- RNA interference of MyD88 reduced HD5's anti-Plasmodium effect.

## Abstract

Malaria poses a serious threat to human health. Existing vector-based interventions have shortcomings, such as environmental pollution, strong resistance to chemical insecticides, and the slow effects of biological insecticides. Therefore, the need to develop novel strategies for controlling malaria, such as reducing mosquito vector competence, is escalating. Human defensin 5 (HD5) has broad-spectrum antimicrobial activity. To determine its effect on Plasmodium development in mosquitoes, HD5 was injected into Anopheles stephensi at various time points. The infection density of Plasmodium yoelii in An. stephensi was substantially reduced by HD5 treatment administered 24 h prior to infection or 6, 12, or 24 h post-infection (hpi). We found that HD5 treatment upregulated the expression of the innate immune effectors TEP1, MyD88, and Rel1 at 24 and 72 hpi. Furthermore, the RNA interference of MyD88, a key upstream molecule in the Toll signaling pathway, decreased the HD5-induced resistance of mosquitoes against Plasmodium infection. These results suggest that HD5 microinjection inhibits the development of malaria parasites in An. stephensi by activating the Toll signaling pathway.